Fibrin binding moieties useful as imaging agents

Details Fibrin binding moieties useful as imaging agents Fibrin binding moieties useful as imaging agents

2006-01-10

2006-01-10

Wax, Robert A. (Department: 1653)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S009322, C424S009411, C424S009500, C530S326000, C530S328000

Reexamination Certificate

active

06984373

ABSTRACT:
The present invention provides binding moieties for fibrin which have a variety of uses wherever detecting, isolating or localizing fibrin, and particularly fibrin as opposed to fibrinogen, is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding fibrin and recognizing the form of polymerized fibrin found in thrombi. In addition, the polypeptides have a slow dissociation rate from fibrin, which improves their ability to form a contrast image at the site of a fibrin clot, making the disclosed binding moieties particularly useful as imaging agents for thrombi.

REFERENCES:
patent: 4808405 (1989-02-01), Smith et al.
patent: 5011686 (1991-04-01), Pang
patent: 5021556 (1991-06-01), Srinivasan
patent: 5075099 (1991-12-01), Srinivasan et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5364612 (1994-11-01), Goldenberg
patent: 5364613 (1994-11-01), Sieving et al.
patent: 5367080 (1994-11-01), Toner et al.
patent: 5632968 (1997-05-01), Goldenberg
patent: 5674469 (1997-10-01), Jablonski
patent: 5720934 (1998-02-01), Dean et al.
patent: 5849261 (1998-12-01), Dean et al.
patent: 5879658 (1999-03-01), Dean et al.
patent: 5886142 (1999-03-01), Thakur et al.
patent: 6001809 (1999-12-01), Thorsett et al.
patent: 0 297 882 (1989-01-01), None
patent: 0347 078 (1989-12-01), None
patent: WO 91/16353 (1991-10-01), None
patent: WO 93/25241 (1993-12-01), None
patent: WO 95/28967 (1995-11-01), None
patent: WO 96/17628 (1996-06-01), None
patent: WO 96/23524 (1996-08-01), None
patent: WO 97/18841 (1997-05-01), None
patent: WO 97/29783 (1997-08-01), None
patent: WO 98/05364 (1998-02-01), None
patent: WO 98/17324 (1998-04-01), None
patent: WO 98/17796 (1998-04-01), None
patent: WO 98/18495 (1998-05-01), None
patent: WO 98/18496 (1998-05-01), None
patent: WO 98/18497 (1998-05-01), None
patent: WO 98/18498 (1998-05-01), None
patent: WO 98/18501 (1998-05-01), None
patent: WO 98/34631 (1998-08-01), None
patent: WO 98/47538 (1998-10-01), None
patent: WO 98/52618 (1998-11-01), None
patent: WO 98/53857 (1998-12-01), None
patent: WO 98/57666 (1998-12-01), None
patent: WO 01/09188 (2001-02-01), None
Alavi et al., “Radiolabeled Antifibrin Antibody in the Detection of Venous Thrombosis: Preliminary Results,”Radiology, 175:79-85 (1990).
Alexander et al., “Intracranial Black-Blood MR Angiography with High-Resolution 3D Fast Spin Echo,”Magnetic Resonance in Medicine,40(2):298-310 (1998).
Anderson and Miller, “Fiber Optic Immunochemical Sensor for Continuous, Reversible Measurement of Phenytoin,”Clin. Chem., 34(7):1417-1421 (1988).
Bautovich et al., “Detection of Deep Venous Thrombi and Pulmonary Embolus with Technetium-99m-DD-3B6/22 Anti-fibrin Monoclonal Antibody Fab′ Fragment,”J. Nucl. Med., 35:195-202 (1994).
Edelman et al., “Extracranial Carotid Arteries: Evaluation with “Black-Blood” MR Angiography,”Radiology, 177(1):45-50 (1990).
Fairbrother et al., “Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site,”Biochemistry, 37:17754-17764 (1998).
Goodrich et al., “A Quantitative Study of Ramped Radio Frequency, Magnetization Transfer, and Slab Thickness in Three-Dimensional Time-of-Flight Magnetic Resonance Angiography in a Patient Population,”Investigative Radiology, 31(6):323-332 (1996).
Gronas et al., “Flow-Independent Angiography for Peripheral Vascular Disease: Initial In-Vivo Results,”Journal of Magnetic Resonance Imaging, 7(4):637-643 (1997).
Harker et al., “Role of Platelets and Thrombosis in Mechanisms of Acute Occlusion and Restenosis After Angioplasty,”Am. J. Cardiology, 60:20B-28B (1987).
Hermans et al., “Fibrin: Structure and Interactions,”Semin. Thromb. Hemost., 8:11-24 (1982).
Hutchinson, “Evanescent Wave Biosensors,”Molec. Biotechnology, 3:47-54 (1995).
Knight et al., “Fragment E1Labled with I-123 in the Detection of Venous Thrombosis,”Radiology, 156:509-514 (1985).
Lanza et al., “High-Frequency Ultrasonic Detection of Thrombi with a Targeted Contrast System,”Ultrasound in Med.&Bio., 23(6):863-870 (1997).
Malmborg et al., “Selection of Binders from Phage Displayed Antibody Libraries Using the BIAcore™ Biosensor,”J. Immunol. Methods, 198(1):51-57 (1996).
Merrifield, “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide,”J. Am. Chem. Soc., 85:2149-2154 (1963).
Moskowitz and Budzynski, “The (DD)E Complex is Maintained by a Composite Fibrin Polymerization Site,”Biochemistry, 33:12937-12944 (1994).
Muto et al., “Initial Clinical Experience with Tc-99m P280, a Synthetic Peptide Useful for Imaging Thrombi and Pulmonary Emboli,”Radiology, 189(Suppl.), 303 (1993).
Olexa et al., “Structure of Fragment E Species from Human Cross-Linked Fibrin,”Biochemistry, 20:6139-6145 (1981).
Palabrica et al., “Thrombus Imaging in a Primate Model with Antibodies Specific for an External Membrane Protein of Activated Platelets,”Proc. Natl. Acad. Sci., 86:1036-1040 (1989).
Rosebrough et al., “Thrombus Imaging: A Comparison of Radiolabeled GC4 and T2G1s Fibrin-Specific Monoclonal Antibodies,”J. Nuc. Med., 31:1048-1054 (1990).
Schuck, “Reliable Determination of Binding Affinity and Kinetics Using Surface Plasmon Resonance Biosensors,”Current Opinion in Biotechnology, 8:498-502 (1997).
Spraggon et al., “Crystal Structures of Fragment D from Human Fibrinogen and its Crosslinked Counterpart from Fibrin,”Nature, 389:455-462 (1997).
Thakur et al., “Indium-lll Labeled Platelets: Studies on Preparation and Evaluation of In Vitro and In Vivo Function,”Throm. Res., 9:345-357 (1976).
Peter et al., “Construction and Functional Evaluation of single-Chain Antibody Fusion Protein with Fibrin Targeting and Thrombin Inhibition After Activation by Factor Xa,”Circulation, 101:1158-1164 (2000).
Achyuthan, K.E. et al., “Factor XIIIa-Derived Peptides Inhibit Transglutaminase Activity”,The Journal of Biological Chemistry,vol. 268, No. 28, pp. 21284-21292, 1993.
Achyuthan, K.E. et al., “Hierarchies in the Binding of Human Factor XIII, Factor XIIIa, and Endothelial Cell Transglutaminase to Human Plasma Fibrinogen, Fibrin, and Fibronectin”,Molecular and Cellular biochemistry,vol. 162, pp. 43-49, 1996.
Achyuthan, K.E. et al., “The Binding Sites on Fibrin(ogen) for Guinea Pig Liver Transglutaminase Are Similar to Those of Blood Coagulation Factor XIII”,The Journal of Biological Chemistry,vol. 163, No. 28, pp. 14296-14301, 1988.
Bevan, M., et al., Accession No. T05787, 1998.
Gray J X et al., “CD97 is a Processed, Seven-Transmembrane, Heterodimeric Receptor Associated with Inflammation,” J of Immun, The Williams and Wilkins Co., vol. 157, No. 12, Dec. 15, 1996.
Greenberg, C.S. et al., Isolation of a Fibrin-Binding Fragment from Blood Coagulation Factor XIII Capable of cross-Linking Fibrin(ogen),Biochem. J.,vol. 256, pp. 1013-1019, 1988.
Greenberg, C.S. et al., “Transglutaminases: Multifunctional Cross-Linking Enzymes that Stabilise Tissues”,The FASEB Journal,vol. 5, pp. 3071-3077, 1991.
Greenwald R.B. et al., “PEG Thiazolidine-2-Thione, a Novel Reagent for Facile Protein Modification: Conjugation of Bovine Hemoglobin”,Bioconjugate Chem.,vol. 7, pp. 638-641, 1996.
Favreau P et al., “Biochemical Characterization and Nuclear Magnetic Resonance Structure of Novel Alpha-Conotoxins Isolated From the Venom of Conus Consors,” Biochemistry, American Chemical Society, vol. 38, No. 19, May 11, 1999.
Fischman, A.J. et al., “A Ticket to Ride: Peptide Radiopharmaceuticals”,J. Nucl. Med.,vol. 34, pp. 2253-2263, 1993.
Hai, T.T et al., Synthesis of Water-Soluble, Nonimmunogenic Polyamide Cross-Linking Agents,Bioconjugate Chem.,vol. 9, pp. 645-654, 1998.
Huang, L. et al., “Coupling of Antibodies

Affiliated with

Also associated with

Rating

Fibrin binding moieties useful as imaging agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fibrin binding moieties useful as imaging agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibrin binding moieties useful as imaging agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3537059